EMEA-001649-PIP02-21
Key facts
| Active substance |
(1S,3S)-3-({2-methyl-6-[1-methyl-5-({[methyl(propyl)carbamoyl]oxy}methyl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}oxy)cyclohexane-1-carboxylic acid (BMS-986278)
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0079/2022
|
| PIP number |
EMEA-001649-PIP02-21
|
| Pharmaceutical form(s) |
All pharmaceutical forms
|
| Condition(s) / indication(s) |
Treatment of fibrosing Interstitial Lung Diseases (ILD)
|
| Route(s) of administration |
All routes of administration
|
| Contact for public enquiries |
Bristol-Myers Squibb EEIG
E-mail: medical.information@bms.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|